Dato-DXd for first treatment of triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study is looking at a new antibody-drug treatment (Dato-DXd) for people with triple-negative breast cancer that has spread and hasn't been treated yet. It's designed to attack cancer cells directly and may be an option for those who can't have immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have triple-negative breast cancer that has spread to other parts of the body or cannot be removed with surgery.
- You haven't had chemotherapy or other systemic treatments for this advanced breast cancer.
- You either tested negative for the PD-L1 marker or, if positive, you have already tried immunotherapy for early-stage breast cancer or cannot receive immunotherapy due to other health conditions.
- You are not pregnant or breastfeeding and are not participating in another clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Dato-DXd for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to help stop the cancer from growing.
This trial is testing whether a new drug combination (Dato-DXd with or without durvalumab) works better than standard chemotherapy plus pembrolizumab for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. The study aims to find a more effective treatment option for this specific group.
This trial studies Dato-DXd (an antibody-drug medicine) in people with triple-negative breast cancer that has spread to the brain. It aims to see how well it controls brain tumors when they are newly found or growing after other treatments.
This trial tests experimental drugs for people with triple-negative breast cancer that came back within 12 months of finishing initial treatment. The goal is to see if these drugs are safe and can shrink or slow the cancer.
This study is testing a drug called T-DXd (a targeted therapy) in people with advanced breast cancer that has HER2 overexpression or underexpression. It looks at how well the drug works in real-world settings, which may provide a new treatment option if your cancer has progressed.
This study tests a new type of targeted therapy called an antibody-drug conjugate (ADC) for advanced breast cancer that is hormone-receptor-positive and HER2-negative. It is for people whose cancer has progressed after CDK4/6 inhibitor treatment, and may offer a new option to slow tumor growth.
Hear when a new Metastatic Triple-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.